



COMMUNIQUE DE PRESSE PRESS RELEASE



GENFIT EXTENDS AND BROADENS ITS PARTNERSHIP WITH SANOFI-AVENTIS THROUGH END OF 2010

Originally devoted to type II diabetes and vascular inflammation, the SAVX1 program adds an additional third component for the treatment of neurodegenerative diseases.

Lille (France), Cambridge (Massachusetts, United States), march 9, 2009 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of research and development of drugs, focusing on early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announced a two-year extension of its partnership with Sanofi-aventis.

The first partnership agreement, signed in 1999, focused on innovative therapeutic target discovery for Type II diabetes and vascular inflammation diseases. AVE0897, a PPAR (Peroxisome Proliferator Agonist Receptor) agonist currently in Phase I clinical trial for diabetes treatment, is a result of this partnership.

The extended agreement announced today includes a third program aiming at discovering new treatments for neurodegenerative diseases. Under the terms of this agreement, Sanofi-aventis will own exclusive rights to commercialize the products resulting from this joint research program. In return, GENFIT will continue to benefit from research funding and future milestone payments and royalties. Financial details of the agreement were not disclosed.

Jean-François Mouney, Chairman of the Management Board of GENFIT, announced: «After 10 years of joint efforts, we are very proud to continue our historic collaboration with Sanofi-aventis. This exemplary alliance, which was successively renewed four times, has been catalyzing the development of drugs to treat major cardiometabolic risk factors. The further extension of our programs to central nervous system field, a therapeutic area where medical needs are growing due to the aging population, confirms the confidence in our research teams by one of the top player in the pharmaceutical industry.»

About GENFIT:

A biopharmaceutical company, GENFIT studies the regulation and function of genes implicated in many of the most widespread diseases. GENFIT's scientists identify new therapeutic targets and develop drug candidates designed specifically for such targets. GENFIT's programs, conducted in partnership with pharmaceutical companies which include SANOFI-AVENTIS, SOLVAY GROUP, PIERRE FABRE, MERCK AG, and SERVIER, treat the most prevalent metabolic diseases. GENFIT's development of proprietary drugs focuses on early diagnosis, prevention and treatment of micro and macro-vascular diseases in pre-diabetes and diabetes. GENFIT is also committed in research programmes in specific neurodegenerative diseases. GENFIT possesses a rich and diversified pipeline of drug candidates at different stages of development – development carried out by GENFIT alone or in partnership. GENFIT's lead proprietary compound, GFT505, is currently in Phase II and another compound in partnership with SANOFI-AVENTIS (AVE0897) is now completing Phase I. With facilities in Lille, France, and Cambridge, MA (USA), the company has over 130 employees on staff, including over 100 scientists. GENFIT is a public company listed on the Alternext by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111).

www.genfit.com



COMMUNIQUE DE PRESSE PRESS RELEASE



About Sanofi-aventis:

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve patients' lives. Sanofi-aventis is both listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Contacts:

GENFIT

Jean-François Mouney - Chairman of the Management Board
+ 33 (0)3 2016 4000

MILESTONES – Press Relations

Bruno Arabian
+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 - milestones@milestones-fr.com

Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company's actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company's prospectus. This press release has been prepared in both French and English languages. In the event of any differences between the two texts, the French language version shall supersede.